RCAR (RenovaCare) Notes Receivable: $0.00 Mil (As of Sep. 2022)


What is RenovaCare Notes Receivable?

RenovaCare RCAR -99.00% Notes Receivable is $0.00 Mil as of Sep. 2022.

RenovaCare's Notes Receivable for the quarter that ended in Sep. 2022 was $0.00 Mil.

RenovaCare Notes Receivable Historical Data

* Premium members only.

The historical data trend for RenovaCare's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RenovaCare Notes Receivable Chart

RenovaCare Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RenovaCare Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RenovaCare Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
RenovaCare (RCAR) has a Notes Receivable of $0.00 Mil as of Sep. 2022. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on RenovaCare and its competitors.
Is RenovaCare's Notes Receivable too high?
RenovaCare's current Notes Receivable is $0.00 Mil.
How does RenovaCare's Notes Receivable compare to ONCSQ and STAB?
RenovaCare's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on RenovaCare and its competitors. RenovaCare's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RenovaCare stock overvalued right now?
RenovaCare (RCAR) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For RenovaCare (RCAR), the current Notes Receivable is $0.00 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RenovaCare Business Description

Address 9375 East Shea Boulvard, Suite 107-A, Scottsdale, AZ, USA, 85260
RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.